Compare · CBLL vs TMDX
CBLL vs TMDX
Side-by-side comparison of CeriBell Inc. (CBLL) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.61B, about 3.8x CBLL ($689.8M).
- Over the past year, CBLL is down 0.4% and TMDX is down 42.0% - CBLL leads by 41.6 points.
- CBLL has been more active in the news (10 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (18 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- TransMedics Group Inc.
- Price
- $18.39+1.27%
- $73.91-2.21%
- Market cap
- $689.8M
- $2.61B
- 1M return
- -1.79%
- +7.36%
- 1Y return
- -0.41%
- -41.98%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2019
- News (4w)
- 10
- 2
- Recent ratings
- 8
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CBLL
- Director Taylor Joseph Michael sold $101,255 worth of shares (5,500 units at $18.41), decreasing direct ownership by 8% to 61,573 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $714,870 worth of shares (39,000 units at $18.33) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 816,317 units (SEC Form 4)
- Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
- Director Tammenoms Bakker Juliet was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Parvizi Josef was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Rogers Erica J. was granted 7,838 shares, increasing direct ownership by 31% to 33,054 units (SEC Form 4)
- Director Burke William W was granted 7,838 shares, increasing direct ownership by 45% to 25,229 units (SEC Form 4)
- Director Taylor Joseph Michael was granted 7,838 shares, increasing direct ownership by 13% to 67,073 units (SEC Form 4)
- Director Robertson Rebecca B was granted 7,838 shares, increasing direct ownership by 42% to 26,587 units (SEC Form 4)
- CeriBell Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest TMDX
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)